Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.61 |
| ▸ | LSS | P48449 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 2/20 | 0.51 |
| ▸ | MMP3 | P08254 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL491881 | 0.93 | KDM4E (0.64) | CACNA1BALDH1A1KDM4ESMN1; SMN2CACNA1H | |
| SCHEMBL4087894 | 0.91 | HRH3 (0.59) | CACNA1BALDH1A1KDM4ESMN1; SMN2CACNA1H | |
| SCHEMBL1700225 | 0.89 | KEAP1 (0.67) | CACNA1BALDH1A1KDM4ESMN1; SMN2CACNA1H | |
| SCHEMBL12460736 | 0.87 | CACNA1B (0.53) | CACNA1BALDH1A1KDM4ESMN1; SMN2CACNA1H | |
| SCHEMBL9671156 | 0.86 | KDM4E (0.83) | ALDH1A1KDM4ESMN1; SMN2HRH3LSS | |
| Hydrochloric Acid SCHEMBL1715021 | 0.86 | CACNA1B (0.52) | CACNA1BALDH1A1KDM4ESMN1; SMN2CACNA1H | |
| SCHEMBL15978587 | 0.85 | KDM4E (0.69) | CACNA1BALDH1A1KDM4ESMN1; SMN2HRH3 | |
| SCHEMBL5276493 | 0.83 | KDM4E (0.56) | CACNA1BALDH1A1KDM4ESMN1; SMN2CACNA1H | |
| SCHEMBL491657 | 0.82 | KDM4E (0.55) | CACNA1BKDM4EHRH3 | |
| SCHEMBL491721 | 0.82 | ATP4A (0.49) | CACNA1BALDH1A1KDM4EMAPTMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281844-A1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SCHWARTZ JEAN-CHARLES (FR) | 2011-11-17 | — | — | US | claimed |
| EP-2000462-A2 | Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications | BIOPROJET (FR) | 2008-12-10 | — | — | EP | claimed |
| EP-1863486-A2 | TREATMENT OF EPILEPSY WITH NON-IMIDAZOLE ALKYLAMINES HISTAMINE H3-RECEPTOR LIGANDS | BIOPROJET (FR) | 2007-12-12 | — | — | EP | claimed |
| WO-2006103537-A2 | TREATMENT OF EPILEPSY WITH NON-IMIDAZOLE ALKYLAMINES HISTAMINE H3-RECEPTOR LIGANDS | BIOPROJET (FR) | 2006-10-05 | — | — | WO | claimed |
| EP-1707203-A1 | Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands | BIOPROJET (FR) | 2006-10-04 | — | — | EP | claimed |
| EP-1707204-A1 | Treatment of epilepsy with non-imidazole alkylamines histamine H3-receptor ligands | BIOPROJET (FR) | 2006-10-04 | — | — | EP | claimed |
| EP-1100503-B1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H 3?-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ILE BIOPROJET SOC CIV (FR) | 2004-09-22 | — | — | EP | claimed |
| EP-1100503-A2 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H 3?-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SOCIETE CIVILE BIOPROJET (FR) | 2001-05-23 | — | — | EP | claimed |
| EP-0982300-A2 | Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications | SOCIETE CIVILE BIOPROJET (FR) | 2000-03-01 | — | — | EP | claimed |
| WO-2000006254-A2 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SOCIETE CIVILE BIOPROJET (FR) | 2000-02-10 | — | — | WO | claimed |
| EP-0978512-A1 | Non-imidazole aryloxy (or arylthio) alkylamines as histamine H3-receptor antagonists and their therapeutic applications | SOCIETE CIVILE BIOPROJET (FR) | 2000-02-09 | — | — | EP | claimed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2025-01-16 | — | — | US | disclosed |
| EP-4474383-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2024-12-11 | — | — | EP | disclosed |
| EP-0511165-B1 | Dicetopyrrolopyrrole compounds | CIBA GEIGY AG (CH) | 1996-08-14 | — | — | EP | disclosed |
| US-5424452-A | A red pigment having at least one substituted pyrrolyl or indolyl-alkoxy group; paints, printing inks; colorfastness, heat and radiation resistance, gloss, weatherproofing | CIBA-GEIGY CORPORATION (US) | 1995-06-13 | — | — | US | disclosed |
| US-5342955-A | Excellent rheological and coloristic properties in paint system and in printing ink | CIBA-GEIGY CORPORATION (US) | 1994-08-30 | — | — | US | disclosed |
| US-5200528-A | Enhanced coloristic and rheological properties, paints, inks | CIBA-GEIGY CORPORATION (US) | 1993-04-06 | — | — | US | disclosed |
| EP-0511165-A2 | Dicetopyrrolopyrrole compounds | CIBA-GEIGY AG (CH) | 1992-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | CACNA1B 4759/4885ALDH1A1 4238/4885KDM4E 3590/4885 |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | CACNA1B 3849/4885ALDH1A1 4457/4885KDM4E 3692/4885 |
| US-20110281844-A1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | HRH3, HRH4, HRH2 | CACNA1B 2798/4885ALDH1A1 3068/4885KDM4E 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.